Welcome! Login | Register
 

Finneran: Too Old, Too White, Too Male To Understand….—why parents would allow their young children---girls specifically---to…

Friday Financial Five – October 31st, 2014—Two positive developments this week include

The Cellar: Wines That Get Better With Time—Invest now and enjoy later....

Worcester Sharks Lose 3-4 to Portland Pirates—The Worcester Sharks (4-2-1-0, 9pts) fell to 2-2-1-0…

See Halloween Band Bash at the Worcester PopUp With Your Woo Card—Let Us WOO You Week of October 30th

Pulitzer-Winning Poet Laureate Trethewey to Speak at Clark—Pulitzer Prize-winner and recent U.S. Poet Laureate Natasha…

Auburn and Greendale Mall to Host Halloween Events—Auburn Mall and Greendale Mall will celebrate Halloween…

Central Mass Grown Receives $60,000 Grant—The Central Massachusetts Regional Planning Commission and the…

7 Reasons To Be Excited About The Celtics Season—Celtics season tips off tonight

Giorgio: Thoughts on the Midterm Senate Election—As we enter the final week of the…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.